1. Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review
- Author
-
José E Mares-Gil, Andrea Judith Bautista-Gómez, Gerardo González-Martínez, María D C Sepúlveda-Orozco, David Alejandro Robles-Sáenz, Miguel Ortiz-Castillo, Daniel A García-Viera, and Laura Villarreal-Martínez
- Subjects
Male ,medicine.medical_specialty ,Central nervous system ,Context (language use) ,Hemorrhage ,Factor VIIa ,Antibodies, Monoclonal, Humanized ,Hemophilia A ,chemistry.chemical_compound ,Antibodies, Bispecific ,Medicine ,Humans ,High titer ,Emicizumab ,Neck pain ,Factor VII ,business.industry ,Hematology ,General Medicine ,Hematoma, Epidural, Spinal ,Recombinant Proteins ,Surgery ,medicine.anatomical_structure ,chemistry ,Child, Preschool ,medicine.symptom ,business ,Bypassing agent ,Spinal epidural hematoma - Abstract
Hemorrhage in the central nervous system is the most severe and debilitating manifestation affecting patients with hemophilia A. The spinal epidural space is the most unusual and clinically challenging site of central nervous system hemorrhage in hemophilia A. These patients often show insidious neurological signs and symptoms that delay diagnosis and treatment. We share our experience treating a 4-year-old male patient with severe hemophilia A and high titer inhibitors with a spontaneous spinal epidural hematoma. The patient presented initially with intense headache and neck pain. After blood tests and imaging studies, bypassing agent therapy with recombinant-activated factor VII was used until discharge; this was later replaced with emicizumab. After 18 months, the patient is without neurological sequelae and has not experienced subsequent bleeding episodes. We review the available literature and discuss the relevance of emicizumab compared with standard therapies in the context of spontaneous spinal epidural hematoma.
- Published
- 2021